REFERENCES
1. National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program. Cancer stat facts: cancer of any site. Available from: https://seer.cancer.gov/statfacts/html/all.html [Last accessed on 19 Feb 2020].
2. Al-Baimani K, Jonker H, Zhang T, Goss GD, Laurie SA, et al. Are clinical trial eligibility criteria an accurate reflection of a real-world population of advanced non-small-cell lung cancer patients? Curr Oncol 2018;25:e291-7.
3. American Society of Clinical Oncology. Two cancer research organizations submit recommendations to FDA aimed at reducing barriers to clinical trial participation. Available from: https://www.asco.org/about-asco/press-center/news-releases/two-cancer-research-organizations-submit-recommendations-fda [Last accessed on 19 Feb 2020].
4. Lin NU, Prowell T, Tan AR, Kozak M, Rosen O, et al. Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research brain metastases working group. J Clin Oncol 2017;35:3760-73.
5. Uldrick TS, Ison G, Rudek MA, Noy A, Schwartz K, et al. Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research HIV working group. J Clin Oncol 2017;35:3774-80.
6. Lichtman SM, Harvey RD, Damiette Smit MA, Rahman A, Thompson MA, et al. Modernizing clinical trial eligibility criteria: recommendations of the american society of clinical oncology-friends of cancer research organ dysfunction, prior or concurrent malignancy, and comorbidities working group. J Clin Oncol 2017;35:3753-9.
7. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of Phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-801.
8. Chen TT, Chute JP, Feigal E, Johnson BE, Simon R. A model to select chemotherapy regimens for Phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst 2000;92:1601-7.
9. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, et al. Twenty-seven years of Phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 2009;4:e7835.
10. Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years? Oncologist 2007;12:1096-104.
11. Small cell Lung Cancer. NCCN clinical practice guidelines in oncology. Version I.2019. Available from: https://www.nccn.org/professionals/physician_gls/pdf/sclc.pdf [last accessed on 19 Feb 2020].
12. Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 2017;377:829-38.
13. Beaver JA, Ison G, Pazdur R. Reevaluating eligibility criteria - balancing patient protection and participation in oncology trials. N Engl J Med 2017;376:1504-5.
14. McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR. A brief report of the status of central nervous system metastasis enrollment criteria for advanced non-small cell lung cancer clinical trials: a review of the ClinicalTrials.gov trial registry. J Thorac Oncol 2016;11:407-13.
